PET Scans Ontario

Physicians: Check this page for notification of changes to the PET request processes, and for other announcements.

Now available: Ga68-DOTATATE PET scanning

Positron Emission Tomography scanning with Gallium-68 DOTATATE (Ga-68 DOTATATE PET) is available in Ontario for patients with neuroendocrine tumours (NETs) as part of the A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment with individualized dosimetry in Patients with 68Ga-DOTATATE identified Somatostatin Receptor Positive Neuroendocrine Tumors (Peptide Receptor Radionuclide Therapy clinical trial [PRRT clinical trial]), however Health Canada approval for use of the Ga-68 DOTATATE in Ontario is limited to this trial only.

For patients who are not eligible to participate in the PRRT clinical trial, their physician may apply for a Ga-68 DOTATATE PET scan out of country, or in another Canadian province (through the PET Access Program), for the following indications:

  • For the initial diagnosis of adult patients with clinical (e.g., signs, symptoms) and biochemical (e.g., markers) suspicion of NETs but for whom conventional imaging is negative or equivocal or for whom biopsy is not easily obtained
  • For the staging of adult patients with localized primary NETs and/or limited metastasis where definitive surgery is planned
  • For determining somatostatin receptor status and suitability for peptide receptor radionuclide therapy
  • For the staging of adult patients with NETs where detection of occult disease will alter the treatment options and decision-making

Location preference is determined by the patient and provider, dependent on the approved indications at individual facilities.

For more information, please contact PET Scans Ontario at 1-877-4PET-411 (1-877-473-8411).

Ontario Clinical Oncology Group (OCOG) Trials Now Accruing

  • PET ABC for the staging of patients with clinical stage III breast cancer
  • PET MUSE for the staging of muscle-invasive urothelial carcinoma of the bladder

For detailed information or to enroll a patient, visit the OCOG website.